You are here: Industry Insights > BMS

News List

BMS Opdivo/Yervoy recommended for untreated kidney cancer via Cancer Drugs Fund pharmafile
April 11, 2019
BMS Opdivo/Yervoy recommended for untreated kidney cancer via Cancer Drugs Fund.
NICE recommends BMS’ Opdivo-Yervoy combination for RCC pharmaceutical-technology
April 09, 2019
Bristol-Myers Squibb (BMS) has announced that the National Institute of Health and Care Excellence (NICE) has recommends Opdivo (nivolumab) and...
BMS, clinging to Opdivo's lung cancer share, highlights long-term data fiercepharma
April 04, 2019
After a hard blow to its hopes in previously untreated lung cancer, Bristol-Myers Squibb is clinging to its share of the second-line market.
BMS signs deal with Concerto HealthAI pharmatimes
April 02, 2019
Bristol-Myers Squibb and Concerto HealthAI have announced plans to apply artificial intelligence (AI) and real-world data to a diverse range of cancers in a multi-year strategic agreement.
Without 'smoking gun,' BMS, Celgene deal will close as planned: analyst fiercepharma
March 20, 2019
Despite staunch disagreement over the merits of the merger, at least one analyst still believes the deal will go through after a vote on April 12.
BMS, Pfizer's Eliquis tops warfarin in high-risk afib subgroup fiercepharma
March 19, 2019
Pfizer and Bristol-Myers Squibb’s next-gen anticoagulant Eliquis has been stealing warfarin market share for years, but that doesn't mean it's slowing down.
BMS deal quest gets a boost as Celgene swats aside another Revlimid patent challenge fiercepharma
March 15, 2019
Much of the investor doubt surrounding Bristol-Myers Squibb’s $74 billion Celgene buyout centers on the multiple myeloma blockbuster Revlimid—namely, whether its remaining patents can stand up to legal challenges. But the companies just scored a win in th
Activist Starboard steps up revolt on Bristol-Celgene merger—and BMS strikes back fiercepharma
March 08, 2019
First came the news that activist investor Starboard Value had bought up shares of Bristol-Myers Squibb with the intention of scuttling its planned $74 billion buyout of Celgene.
Pharma Can BMS rebels scuttle its Celgene buy? Analysts do the math—and so far, the votes don't add up fiercepharma
March 04, 2019
Bristol-Myers Squibb shareholders panicked on Wednesday when its largest institutional shareholder, Wellington Management, came out against its $74 billion acquisition of Celgene—and activist hedge fund Starboard Value immediately followed suit.
CytomX slumps as BMS bails on 3 partnered projects fiercebiotech
February 28, 2019
Amid an R&D update from CytomX is the news that Bristol-Myers Squibb has abandoned three programs, putting pressure on the biotech’s share price....

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page